Eris Lifesciences has announced the allotment of 1,55,264 equity shares under its ESOP-2021 Scheme. The allotment, made on September 22, 2026, resulted from the exercise of options by employees. This action has led to an increase in the company’s paid-up share capital to ₹13,87,38,569, reflecting the expanded share base and enhanced equity structure.
Equity Share Allotment Under ESOP Scheme
Eris Lifesciences Limited has officially informed stakeholders about the allotment of 1,55,264 equity shares. This issuance is pursuant to the exercise of options under the company’s ESOP-2021 Scheme. The allotment date was September 22, 2026.
Details of ESOP Allotment
The shares were allotted under different grant years with varying issue prices:
- 2022 Grant: 66,422 shares at ₹557.24 per share.
- 2023 Grant: 57,239 shares at ₹510.32 per share.
- 2024 Grant: 31,603 shares at ₹728.16 per share.
Impact on Share Capital
The allotment of these equity shares has resulted in an increase in Eris Lifesciences’ paid-up share capital. The capital has moved from ₹13,85,83,305 (representing 13,85,83,305 equity shares of ₹1/- each) to ₹13,87,38,569 (representing 13,87,38,569 equity shares of ₹1/- each).
Source: BSE
